Xenon Pharmaceuticals Inc. (XENE)

NASDAQ: XENE · IEX Real-Time Price · USD
43.05
+0.05 (0.12%)
Mar 28, 2024, 4:00 PM EDT - Market closed
0.12%
Market Cap 3.25B
Revenue (ttm) n/a
Net Income (ttm) -182.39M
Shares Out 75.43M
EPS (ttm) -2.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 307,762
Open 42.88
Previous Close 43.00
Day's Range 42.38 - 43.55
52-Week Range 27.99 - 50.99
Beta 1.17
Analysts Strong Buy
Price Target 57.30 (+33.1%)
Earnings Date May 7, 2024

About XENE

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 5, 2014
Employees 259
Stock Exchange NASDAQ
Ticker Symbol XENE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for XENE stock is "Strong Buy." The 12-month stock price forecast is $57.3, which is an increase of 33.10% from the latest price.

Price Target
$57.3
(33.10% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days

VANCOUVER, British Columbia, March 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present a...

16 days ago - GlobeNewsWire

Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024

VANCOUVER, British Columbia, March 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present a...

23 days ago - GlobeNewsWire

Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

XEN1101 Phase 3 epilepsy program continues to progress with X-TOLE2 and X-TOLE3 in focal onset seizures and X-ACKT in primary generalized tonic-clonic seizures; completion of patient enrollment  in X-...

4 weeks ago - GlobeNewsWire

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update

VANCOUVER, British Columbia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its fourth quarte...

5 weeks ago - GlobeNewsWire

Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024

Completion of Patient Enrollment in XEN1101 Phase 3 X-TOLE2 Clinical Trial in Focal Onset Seizures Anticipated in Second Half of 2024

2 months ago - GlobeNewsWire

Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

VANCOUVER, British Columbia, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at...

3 months ago - GlobeNewsWire

Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

VANCOUVER, British Columbia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the closing of its previously an...

4 months ago - GlobeNewsWire

Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)

VANCOUVER, British Columbia, Dec. 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will provide updates on its n...

4 months ago - GlobeNewsWire

Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering

VANCOUVER, British Columbia, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE) (“Xenon”), a neurology-focused biopharmaceutical company, today announced the pricing of its ups...

4 months ago - GlobeNewsWire

Xenon Pharmaceuticals Announces Proposed Public Offering

VANCOUVER, British Columbia, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE) (“Xenon”), a neurology-focused biopharmaceutical company, today announced that it has commenced ...

4 months ago - GlobeNewsWire

Xenon Pharmaceuticals' stock falls as depression treatment has mixed results in clinical trial

Shares of Xenon Pharmaceuticals Inc. XENE fell 1.6% premarket on Monday after the neurology-focused company released new data from a clinical trial of its lead asset, an experimental depression treatm...

4 months ago - Market Watch

Canada's Xenon Pharma's depression drug fails to meet main goal in study

Canada's Xenon Pharmaceuticals said on Monday that its experimental drug to treat moderate to severe major depressive disorder (MDD) had failed to significantly reduce the severity of depressive episo...

4 months ago - Reuters

Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)

VANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported topline results from the randomiz...

4 months ago - GlobeNewsWire

Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences

Phase 2 Proof-of-Concept Study of NBI-921352 in Patients with Focal Onset Seizures Failed to Demonstrate Meaningful Reduction in Seizure Frequency Phase 2 Proof-of-Concept Study of NBI-921352 in Patie...

5 months ago - GlobeNewsWire

Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Topline data from XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder  on track for late November to mid-December

5 months ago - GlobeNewsWire

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Corporate Update

VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter...

5 months ago - GlobeNewsWire

Xenon Pharmaceuticals Announces Publication of Results from XEN1101 Phase 2b “X-TOLE” Clinical Trial in Peer-Reviewed Journal Article in JAMA Neurology

VANCOUVER, British Columbia, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the medical journal JAMA Neurolo...

6 months ago - GlobeNewsWire

Xenon Pharmaceuticals to Present at Jefferies Inaugural Biotech CNS/Neuro Summit

VANCOUVER, British Columbia, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at...

6 months ago - GlobeNewsWire

Xenon Pharmaceuticals to Present at TD Cowen's 3rd Annual Novel Mechanisms in Neuropsychiatry Summit

VANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present a...

7 months ago - GlobeNewsWire

Xenon Pharmaceuticals Announces Upcoming Investor Webinar with Leading Key Opinion Leaders to Discuss XEN1101 and Major Depressive Disorder

Live broadcast of webinar on Tuesday, September 19 beginning at 11:30 am ET Live broadcast of webinar on Tuesday, September 19 beginning at 11:30 am ET

7 months ago - GlobeNewsWire

Xenon Pharmaceuticals Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress

New interim data from ongoing Phase 2b X-TOLE open-label extension demonstrates improvement in overall quality-of-life (QoL) when compared to baseline

7 months ago - GlobeNewsWire

Xenon Pharmaceuticals to Present at the Wells Fargo 2023 Healthcare Conference

VANCOUVER, British Columbia, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at...

7 months ago - GlobeNewsWire

Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Last patient enrolled in XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder  with topline data expected in late November to mid-December

8 months ago - GlobeNewsWire

Xenon Pharmaceuticals Expands Leadership on its Board of Directors with Appointments of Gillian M. Cannon and Justin Gover

VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced two new appointments to its Boar...

8 months ago - GlobeNewsWire

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Corporate Update

VANCOUVER, British Columbia, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its second quarte...

8 months ago - GlobeNewsWire